EU Clinical Trial Blueprint: Unpacking the MDCG 2024-3 Guidance

This episode dissects the critical MDCG 2024-3 guidance issued in March 2024, which outlines the European Union's expectations for a Clinical Investigation Plan (CIP). We explore how this document harmonizes the EU MDR and ISO 14155:2020, establishing the best-practice blueprint for planning medical device studies. We break down the essential components your CIP must include, from the benefit-risk analysis and statistical design to data management and safety reporting, to ensure a successful regulatory submission. Key Questions: • What is the MDCG 2024-3 guidance, and why is it crucial for MedTech manufacturers? • How does this document unify the requirements of the EU MDR and ISO 14155:2020? • What are the core sections your Clinical Investigation Plan must now feature? • How should you structure the benefit-risk analysis to meet regulatory expectations? • What are the new guidelines for detailing statistical methods and data management? • How does the guidance address modifications, deviations, and adverse event reporting? • Is your current approach to clinical investigations compliant with these latest EU standards? • What information is required to demonstrate the scientific validity of your study design? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.